Sonoco Products Company

SONNYSEUSD

THESIS ALERT

Email me when the SON thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$49.60
−$0.19 (−0.38%)Today 1M +3.51%
After hours$49.600.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$49.79
Prior regular-session close from the quote source.
$49.13–$49.79
Regular-session low and high so far today.
972.9K
Regular-session shares traded · Nov 11, 4:00 PM ET.
Feb 16 projected
Projected for 2027-02-16 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$39.27–$60.67
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own SON if that integration and pricing power exceed the low expectations already priced in.

SON price history

Latest price$49.60Today−$0.19 (-0.38%)
SON +2.11%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

3 MATERIAL PROPOSITIONS
  • Sonoco’s portfolio transformation (Eviosys buy + TFP/ThermoSafe sales) will sustainably raise margins by shifting revenue mix toward higher-margin metal and engineered consumer packaging and removing lower-return businesses.StrengtheningMateriality: High

    operating_income rose from 326,578,000 (FY2024) to 1,017,735,000 (FY2025). If true, operating margin and free-cash generation should remain above historical pre-transformation levels and justify a multiple expansion; if false, the 2025 margin gains will revert and capital returns will be constrained.

    Watch: Failure to integrate Eviosys operations causing lost synergies, production disruption or customer churn.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_income rose from 326,578,000 (FY2024) to 1,017,735,000 (FY2025).

    Open source ↗
  • The Eviosys acquisition secures global customer relationships and product breadth that provide pricing power and organic growth opportunities in metal packaging, supporting revenue durability and higher gross margins.HoldingMateriality: High

    revenue increased from 5,305,365,000 (FY2024) to 7,518,753,000 (FY2025) coincident with the Eviosys acquisition and portfolio changes. If Eviosys gives Sonoco differentiated, sustainable share with strategic customers, revenue and gross margin will be steadier and less cyclical; if customers defect or competition matches capabilities, revenue will weaken and margin gains disappear.

    Watch: Competitors or large customers vertically integrating into metal packaging, reducing Sonoco’s addressable market.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    revenue increased from 5,305,365,000 (FY2024) to 7,518,753,000 (FY2025) coincident with the Eviosys acquisition and portfolio changes.

    Open source ↗
  • Sonoco’s operations will generate positive and sufficient operating cash flow to fund dividends, deleveraging and selective M&A after integration costs, because core packaging is cash-generative.HoldingMateriality: Medium

    operating_cash_flow has been positive across recent years: 882,918,000 (FY2023), 833,845,000 (FY2024), 689,782,000 (FY2025). If operating cash flow holds up, the company can pursue value-accretive investments and maintain shareholder returns; if cash flow weakens materially, dividend/multiple risk and leverage constraints rise.

    Watch: Working-capital strains or integration-related capex that materially reduce free cash flow conversion.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_cash_flow has been positive across recent years: 882,918,000 (FY2023), 833,845,000 (FY2024), 689,782,000 (FY2025).

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Sonoco’s portfolio transformation (Eviosys buy + TFP/ThermoSafe sales) will sustainably raise margins by shifting revenue mix toward higher-margin metal and engineered consumer packaging and removing lower-return businesses. If true, operating margin and free-cash generation should remain above historical pre-transformation levels and justify a multiple expansion; if false, the 2025 margin gains will revert and capital returns will be constrained.

The Eviosys acquisition secures global customer relationships and product breadth that provide pricing power and organic growth opportunities in metal packaging, supporting revenue durability and higher gross margins. If Eviosys gives Sonoco differentiated, sustainable share with strategic customers, revenue and gross margin will be steadier and less cyclical; if customers defect or competition matches capabilities, revenue will weaken and margin gains disappear.

Sonoco’s operations will generate positive and sufficient operating cash flow to fund dividends, deleveraging and selective M&A after integration costs, because core packaging is cash-generative. If operating cash flow holds up, the company can pursue value-accretive investments and maintain shareholder returns; if cash flow weakens materially, dividend/multiple risk and leverage constraints rise.

All standing thesis claims
Original report summary

that integration and pricing power exceed the low expectations already priced in.

Evidence assessed Nov 3, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Sonoco Products Co

Where the evidence on Sonoco Products Co stands: Holding on the latest evidence (Nov 3, 2026). Of its 3 thesis points, 1 strengthening and 2 holding.

Bull case: what the evidence supports

  • Sonoco’s portfolio transformation (Eviosys buy + TFP/ThermoSafe sales) will sustainably raise margins by shifting revenue mix toward higher-margin metal and engineered consumer packaging and removing lower-return businesses.

    sec.gov ↗

  • The Eviosys acquisition secures global customer relationships and product breadth that provide pricing power and organic growth opportunities in metal packaging, supporting revenue durability and higher gross margins.

    sec.gov ↗

  • Sonoco’s operations will generate positive and sufficient operating cash flow to fund dividends, deleveraging and selective M&A after integration costs, because core packaging is cash-generative.

    sec.gov ↗

Bear case: what would count against it

  • Failure to integrate Eviosys operations causing lost synergies, production disruption or customer churn.

    sec.gov ↗

  • Competitors or large customers vertically integrating into metal packaging, reducing Sonoco’s addressable market.

    sec.gov ↗

  • Working-capital strains or integration-related capex that materially reduce free cash flow conversion.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Sonoco Products Co

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

Loading the break-condition record for Sonoco Products Co.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

No assessed change was returned in this research window. That can reflect a quiet period or a coverage limit.

Risks / falsifiers

What could break the thesis

  • Failure to integrate Eviosys operations causing lost synergies, production disruption or customer churn.
  • Competitors or large customers vertically integrating into metal packaging, reducing Sonoco’s addressable market.
  • Working-capital strains or integration-related capex that materially reduce free cash flow conversion.

SON news

Loading headlines…

Financial statements

SON income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

SON: quick answers

When does Sonoco Products Co (SON) report earnings next?
Sonoco Products Co's next results are projected for February 16, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on October 21, 2026. Earnings calendar
What is SON's short interest?
As of October 30, 2026, 11.7M SON shares were sold short, 11.8% of its shares outstanding, down 2.2% from the count before. At the stock's average daily volume that is 7.1 days to cover. FINRA publishes the count twice a month. SON short interest history
Have members of Congress traded SON?
6 trades in SON have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed SON trade
Which well-known investors own SON?
1 of the 37 well-known funds tracked here reported SON shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

SON in well-known investors’ portfolios

1 of 37 funds reported SON shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.02%$5.8M−44.2%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.